Get the Stockscreener App
8.73
4.07%
-0.37
After Hours:
8.73
Avita Medical Inc Stock (RCEL) Latest News
How To Trade (RCEL) - Stock Traders Daily
Avita Medical LimitedADR to Host Earnings Call - ACCESS Newswire
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference - The Manila Times
Can AVITA Medical's Conference Appearance Signal New Growth Opportunities in Wound Care? - StockTitan
Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical - openPR
D. Boral Capital Lowers AVITA Medical (NASDAQ:RCEL) Price Target to $22.00 - MarketBeat
AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O'toole Buys 1,000 Shares - MarketBeat
Insider Buying: Robert Mcnamara Acquires 10,000 Shares of AVITA Medical Inc (RCEL) - GuruFocus.com
Insider Buying: AVITA Medical, Inc. (NASDAQ:RCEL) Director Acquires 10,000 Shares of Stock - MarketBeat
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know - MSN
Avita medical CFO David O'Toole acquires $9,900 in common stock - Investing.com Australia
Avita Medical director Robert McNamara purchases $100,900 in stock By Investing.com - Investing.com South Africa
Avita medical CFO David O’Toole acquires $9,900 in common stock - Investing.com India
Avita Medical director Robert McNamara purchases $100,900 in stock - Investing.com India
Avita medical CFO David O'Toole acquires $9,900 in common stock By Investing.com - Investing.com South Africa
AVITA Medical, Inc. (RCEL): A Bull Case Theory - Insider Monkey
When (RCEL) Moves Investors should Listen - Stock Traders Daily
D. Boral Capital Reiterates Buy Rating for AVITA Medical (NASDAQ:RCEL) - MarketBeat
After Sales Rebound In January, AVITA Is Set Up For A Monster Year - Seeking Alpha
AVITA Medical (NASDAQ:RCEL) Posts Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
AVITA Medical's SWOT analysis: regenerative medicine firm's stock faces growth hurdles - Investing.com
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2024 Earnings Call Transcript - Insider Monkey
Avita Medical targets $3.5B TAM with expanded portfolio amid Cohealyx launch in 2025 - MSN
Avita medical director Suzanne Crowe buys $6,390 in stock - MSN
AVITA Medical Reports Transformative Year Amidst Challenges - TipRanks
AVITA Medical Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Stro - GuruFocus.com
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Cantor maintains Avita stock Overweight with $19 target - MSN
AVITA Medical to Host Investor Webinar Briefing - The Manila Times
Inside AVITA Medical's 2024 Performance: CEO & CFO Reveal Growth Strategy - StockTitan
Analyst Expectations For AVITA Medical's Future - Benzinga
2 ASX All Ords shares soaring on strong full year results - The Motley Fool Australia
Avita Medical earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
AVITA Medical Inc (RCEL) Q4 Earnings: EPS of -$0.44 Misses Estimate, Revenue of $18.4M Falls Short - GuruFocus.com
Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12% -February 13, 2025 at 10:41 pm EST - Marketscreener.com
AVITA Medical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results - The Capital Club
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FDA Approves RECELL GO mini - MPO-mag
Wound Closure Devices Market to See Drastic Growth – Post 2025 | AVITA Medical, ConvaTec, Organogenesis - Newstrail
Trend Tracker for (RCEL) - Stock Traders Daily
AVITA gets FDA clearance for Cohealyx for wound care - MSN
Terry Bromley Chosen to Lead Imbed Biosciences - MPO-mag
FDA Clears AVITA Medical’s Cohealyx Dermal Matrix - MPO-mag
1.02%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):